• Carl Webster

    Principal Scientist
    MedImmune

Carl Webster has a BSc in biochemistry from Bath University and a PhD in Molecular Biology from Leicester University. He followed his education with a post doctoral position at Cambridge University on the role of high mobility group proteins in gene regulation. Carl was recruited to CAT in 1997 and initially worked in teams using antibody phage display libraries for gene discovery and target validation. He has worked on a number of projects with CAT’s partners, isolating antibodies to therapeutic targets. In 2000, he set up CAT’s antigen expression and molecular biology team providing gene cloning, and expression technologies for antigens and scFv, and real time PCR to CAT’s drug programmes. He is now Principal Scientist, ADPE for MedImmune, leading teams using protein engineering for the development of novel therapeutics and for blood brain barrier transport.


  • Professor Roosmarijn Vandenbroucke


    Ghent University

Roosmarijn Vandenbroucke is a Professor in the Barriers and Inflammation group, in the Inflammation Research Center at Ghent University in Belgium. Her lab focusses on investigating the effect of systemic inflammation and Neuroinflammation on the blood-cerebrospinal fluid barrier (BCSFB). More specifically, the lab studies molecules that play key roles in detrimental processes at the BCSFB during inflammation, focussing on barrier integrity, exosome and acute phase response. The research group also investigate the potential of the choroid plexus endothelium to be used as a delivery route to the brain.


  • Professor Margareta Hammarlund-Udenaes


    Uppsala University, Sweden

Dr Hammarlund-Udenaes is Professor of Pharmacokinetics and Pharmacodynamics since 1999. She received her Ph.D. in Pharmaceutical Sciences in 1984 from Uppsala University. She has supervised 13 PhD’s and published more than 80 original articles. She became an AAPS Fellow in 2005. Her research is focused on the pharmacokinetics of blood-brain barrier transport of drugs in relation to central effects and side-effects. The influence of drug transport processes on drug delivery to the brain is theoretically as well as experimentally studied with microdialysis, PET and other methods. In vitro methods and new concepts for brain drug delivery are developed based on the in vivo principles.


  • Professor John Greenwood


    Institute of Opthmalmology, UCL

Professor John Greenwood is the Hugh Davson Professor of Biomedical Research and Head of the Department of Cell Biology at the UCL Institute of Ophthalmology, University College London. He obtained his PhD from the Institute of Psychiatry, University of London following a study of transport systems at the blood-brain barrier. After a postdoctoral fellowship at King’s College London, he was awarded the Renee Hock Fellowship at the UCL Institute of Ophthalmology, University College London in 1990 to study the blood-retinal barrier in retinal inflammatory disease. In 1993 he was made Senior Lecturer at the Institute of Ophthalmology and in 2000 Full Professor. His research staff occupies state-of-the-art laboratories in the Henry Wellcome Building for Translational Eye Research. The vasculature of the brain and retina in health and disease remain a major focus of his research. Work from the Greenwood laboratory has been at the forefront of identifying and characterising novel endothelial cell mechanisms that facilitate the recruitment of leukocytes to the central nervous system, a critical step in the pathogenesis of diseases such as multiple sclerosis and posterior uveitis. In recent years the core focus has been to identify and study novel drivers of vascular pathology in the retina and in particular factors that contribute to the development of pathogenic neovascularisation and vessel remodelling.


  • Professor Ignacio Romero

    Professor in Cellular Neuroscience
    The Open University

Dr Ignacio (Nacho) Romero is a Senior Lecturer of Cellular Neuroscience at The Open University, United Kingdom. He obtained his PhD from King’s College London in 1993 on the toxicology of the blood-brain barrier (BBB) and has since contributed to over 80 publications and reviews on various aspects related to BBB physiology and pathophysiology, particularly in neuroinflammation. He was a post-doctoral fellow at the Institut Cochin de Génétique Moléculaire, in Paris, and at the Institute of Ophthalmology, University College London, before being appointed to faculty at The Open University. He is currently the Director of the Biomedical Research Network and heads a group focused on the biology of the neurovascular unit at the cellular level both in health and disease. His more recent research focuses on understanding the molecular mechanisms underlying BBB dysfunction in several disease states, such as Alzheimer’s disease and multiple sclerosis, and in ageing. In particular, he is currently investigating the transcriptional and post-transcriptional regulation of human brain endothelial cell phenotype under normal and inflammatory conditions.


  • Professor Gert Fricker


    Heidelberg University

Professor Gert Fricker studied chemistry and medicine at the University of Freiburg. After obtaining his doctorate in biochemistry, he completed his habilitation in experimental medicine in 1993. Following a postdoc position at University Hospital of Zurich, he then joined the Drug Delivery System department at Sandoz AG in Basel in 1988. In 1995, he accepted a position at the Institute for Pharmaceutical Technology and Biopharmacy at the University of Heidelberg. Appointed Director of the new Institute of Pharmacy and Molecular Biotechnology in 2002, he is also Managing Director of the Heidelberg-based Steinbeis Technology Transfer Centre Biopharmacy and Analytics. His research interests include membrane transport processes, innovative dosage forms and API transport through the blood-brain barrier.


  • Professor David Begley


    Kings College London


  • Professor Alan Stitt

    Chair of Experimental Ophthalmology
    Queen’s University Belfast

Professor Alan Stitt was appointed to the McCauley Chair of Experimental Ophthalmology in Queen’s University Belfast, in March 2001. He is also the Director of the newly formed Centre for Vision & Vascular Science (CVVS) in Queen’s Medical School. He has published over 120 scientific manuscripts in the inter-related areas of the biology of advanced glycation, pathogenesis of diabetic retinopathy and retinal angiogenesis. Professor Stitt was awarded a Royal Society – Wolfson Merit Award in December 2010.


  • PIETER J. GAILLARD , PhD

    Co-founder and CEO
    2-BBB Medicines BV

Dr. Pieter J. Gaillard is a scientist, inventor and entrepreneur. He obtained a master degree in biomedical sciences from Utrecht University and a PhD degree in pharmacology from Leiden University, The Netherlands. In 2003 he founded and is now restarting the company to-BBB after the bankruptcy in 2015 (2-BBB). Meanwhile he started a new therapeutic eye care company (Eyesiu). He is a member of the expert board at Skolkovo Foundation in Russia, advisory board at the Leiden BioSciencePark and member of the Supervisory Board of Leiden Marketing. With his team at to-BBB, he successfully raised six rounds of equity investments, ranging from seed to series C venture capital, and numerous non-dilutive credits and grants. In 2008, he licensed the GTechnology® from a Taiwanese research and technology institute (ITRI) as the company’s new and improved brain delivery platform. As to-BBB’s chief scientific officer, he effectively led the company through the discovery and preclinical phases of drug development, delivering the company’s lead product 2B3-101 in a clinical phase I/IIa brain cancer trial in 2011, and the company’s second product 2B3-201 for acute relapses in MS in a phase I trial in 2013. In the meantime, he and his team established numerous research collaborations with top tier pharmaceutical companies, foundations and academic groups to combine to-BBB’s innovative approach with their potential drugs in development.


  • Markus Schwaninger

    Professor of Pharmacology and Toxicology
    University of Lübeck

Markus Schwaninger is Professor of Pharmacology and Toxicology, and Chairman of the Institute of Experimental and Clinical Pharmacology and Toxicology at the University of Lübeck. He obtained his PhD at the University of Freiburg in 1986, following a study of endogenous opioids in the rat pituitary gland, and obtained the Fritz Külz prize of the German Society for Pharmacology and Toxicology in 1988. The Schwaninger lab has focussed research on neuroinflammation signalling pathways in ischaemia, specifically the effect of peripheral metabolic factors on inflammation in the brain. More recently, research has focussed on gene therapy targeting at the blood-brain barrier, as a potential treatment for neurological disease.


  • Krzysztof Wicher

    Principal Scientist
    Ossianix

Krzysztof Wicher defended his PhD thesis in physiological chemistry at the Medical Faculty, Uppsala University, Sweden in 2006. Until 2013, he held post-doctoral positions at the London Research Institute, Cancer Research UK and at the Gurdon Institute, University of Cambridge, working on RNA localization and molecular aspects of cell differentiation in early animal development. Later, he worked as a Scientist at Medimmune, in the Antibody Development and Protein Engineering department, working on novel biological therapeutics formats. Since the beginning of 2015, Krzysztof has been working as Senior Scientist and then Principal Scientist at Ossianix, developing a BBB penetrant shark antibody platform.


  • Dr Ingolf Blasig


    Leibniz-Institut for Molekulare Pharmakologie

Ingolf Blasig studied biology and biochemistry in Leipzig from 1970-74. His diploma thesis was on cancer research at the Robert-Rössle-Hospital in Berlin, his dissertation dealt with the pharmacology of myocardial infarction at the Academy of Sciences (1984). He obtained his venia legendi for investigations on myocardial dysfunction at the University of Halle in 19992. From 1993-95, he was awarded project leader at the NIH, USA. Since 1992 he has been head of the independent research group for Molecular Cell Physiology at the FMP and is teaching at the universities in Potsdam and Berlin.


  • Ijeoma Uchegbu

    CSO
    Nanomerics

Ijeoma Uchegbu is Professor of Pharmaceutical Nanoscience within the UCL School of Pharmacy.  She obtained her PhD from the School of Pharmacy in 1994 and was appointed to a lectureship in Drug Delivery in 1997 within the University of Strathclyde.  She became a Senior Lecturer in 2000 and a Professor of Drug Delivery in 2002.  She then joined the School of Pharmacy as a Professor of Pharmaceutical Nanoscience in 2006 and joined UCL in 2012.  In 2010, Ijeoma became cofounder and Chief Scientific Officer of Nanomerics Ltd, a specialty pharmaceutical company and spin-out from UCL. Ijeoma has won numerous prizes for her work including the UK Department of Business Innovation and Skills’ Women of Outstanding Achievement Award in 2007, and the Royal Pharmaceutical Society Pharmaceutical Scientist of the Year Award in 2012.


  • Dr Michel Khrestchatisky

    CNRS, Co-founder and Scientific Counsel Vect-Horus
    Vect-Horus

Dr Michel Khrestchatisky is a first–class Research Director at the CNRS and holds a PhD in cellular and molecular biology. He specialized in neurobiology, conducting 4 years of research at the University of California Los Angeles (UCLA, USA) and has 10 years of experience as Group Leader at INSERM, Paris. He has held the post of Director for the last 12 years of the NICN-UMR7259 Neurobiology Laboratory, supported by the CNRS and Aix-Marseille University. He is also leader of the BBB and Neuroinflammation group. Dr Khrestchatisky has published over 100 peer-reviewed articles in international scientific journals, a dozen book chapters and is co-inventor in 5 families of patents.


  • Dr Matthew Campbell


    Trinity College Dublin

Having obtained a Fighting Blindness Research scholarship in 2002, Dr Matthew Campbell graduated from University College Dublin (UCD) in 2006 with a PhD in Biochemistry focusing on the role of tight junctions in the development of the degenerative eye conditions diabetic retinopathy (DR) and age-related macular degeneraton (AMD). In the same year, he joined the Genetics department in TCD and focused his interests primarily around the molecular biology and physiology of the vasculature associated with neural tissues. He has published extensively on the use of RNA interference (RNAi) to modulate levels of distinct tight junction proteins at the blood-brain barrier/inner blood retina barrier (BBB/iBRB) in vivo.


  • Dr. Heiko Manninga

    Managing Director and Chief Scientific Officer
    NEUWAY Pharma